Software - Application
Compare Stocks
5 / 10Stock Comparison
RMNI vs SPWR vs USPH vs MANH vs EPAM
Revenue, margins, valuation, and 5-year total return — side by side.
Solar
Medical - Care Facilities
Software - Application
Information Technology Services
RMNI vs SPWR vs USPH vs MANH vs EPAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Software - Application | Solar | Medical - Care Facilities | Software - Application | Information Technology Services |
| Market Cap | $362M | $866M | $897M | $8.50B | $5.51B |
| Revenue (TTM) | $423M | $315M | $695M | $1.10B | $5.56B |
| Net Income (TTM) | $35M | $-42M | $11M | $217M | $387M |
| Gross Margin | 59.9% | 50.4% | 22.0% | 55.6% | 28.5% |
| Operating Margin | 13.7% | -2.7% | 12.2% | 25.6% | 9.9% |
| Forward P/E | 9.5x | 5.1x | 20.6x | 26.8x | 8.2x |
| Total Debt | $28M | $188M | $426M | $112M | $144M |
| Cash & Equiv. | $120M | $10M | $36M | $329M | $1.30B |
RMNI vs SPWR vs USPH vs MANH vs EPAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 23 | May 26 | Return |
|---|---|---|---|
| Rimini Street, Inc. (RMNI) | 100 | 144.9 | +44.9% |
| SunPower Inc. (SPWR) | 100 | 30.0 | -70.0% |
| U.S. Physical Thera… (USPH) | 100 | 50.7 | -49.3% |
| Manhattan Associate… (MANH) | 100 | 75.3 | -24.7% |
| EPAM Systems, Inc. (EPAM) | 100 | 44.1 | -55.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RMNI vs SPWR vs USPH vs MANH vs EPAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RMNI is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.49 vs MANH's 1.25
- PEG 0.49 vs 0.70
- +18.3% vs SPWR's -42.4%
SPWR lags the leaders in this set but could rank higher in a more targeted comparison.
USPH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- Beta 0.93, yield 3.1%, current ratio 1.01x
- 16.3% revenue growth vs RMNI's -1.7%
MANH ranks third and is worth considering specifically for long-term compounding.
- 145.1% 10Y total return vs USPH's 22.6%
- 19.7% margin vs SPWR's -13.2%
- 28.0% ROA vs SPWR's -19.5%, ROIC 236.8% vs -5.3%
EPAM is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.21, Low D/E 3.9%, current ratio 2.59x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs RMNI's -1.7% | |
| Value | PEG 0.49 vs 0.70 | |
| Quality / Margins | 19.7% margin vs SPWR's -13.2% | |
| Stability / Safety | Beta 0.93 vs SPWR's 2.13 | |
| Dividends | 3.1% yield; 5-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +18.3% vs SPWR's -42.4% | |
| Efficiency (ROA) | 28.0% ROA vs SPWR's -19.5%, ROIC 236.8% vs -5.3% |
RMNI vs SPWR vs USPH vs MANH vs EPAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RMNI vs SPWR vs USPH vs MANH vs EPAM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MANH leads in 2 of 6 categories
RMNI leads 2 • USPH leads 1 • SPWR leads 0 • EPAM leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MANH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EPAM is the larger business by revenue, generating $5.6B annually — 17.7x SPWR's $315M. MANH is the more profitable business, keeping 19.7% of every revenue dollar as net income compared to SPWR's -13.2%. On growth, USPH holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $423M | $315M | $695M | $1.1B | $5.6B |
| EBITDAEarnings before interest/tax | $63M | -$6M | $107M | $288M | $684M |
| Net IncomeAfter-tax profit | $35M | -$42M | $11M | $217M | $387M |
| Free Cash FlowCash after capex | $47M | -$15M | $67M | $380M | $544M |
| Gross MarginGross profit ÷ Revenue | +59.9% | +50.4% | +22.0% | +55.6% | +28.5% |
| Operating MarginEBIT ÷ Revenue | +13.7% | -2.7% | +12.2% | +25.6% | +9.9% |
| Net MarginNet income ÷ Revenue | +8.3% | -13.2% | +1.5% | +19.7% | +7.0% |
| FCF MarginFCF ÷ Revenue | +11.0% | -4.6% | +9.6% | +34.5% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.2% | -0.2% | +7.7% | +7.4% | +7.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -72.1% | -101.3% | -115.0% | -3.5% | +18.8% |
Valuation Metrics
RMNI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 10.1x trailing earnings, RMNI trades at a 76% valuation discount to USPH's 41.5x P/E. Adjusting for growth (PEG ratio), RMNI offers better value at 0.52x vs EPAM's 4.18x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $362M | $866M | $897M | $8.5B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $269M | $1.0B | $1.3B | $8.3B | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | 10.10x | -15.25x | 41.55x | 39.88x | 15.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.53x | 5.10x | 20.63x | 26.79x | 8.17x |
| PEG RatioP/E ÷ EPS growth rate | 0.52x | — | — | 1.86x | 4.18x |
| EV / EBITDAEnterprise value multiple | 7.30x | — | 12.52x | 28.67x | 6.74x |
| Price / SalesMarket cap ÷ Revenue | 0.86x | 2.80x | 1.15x | 7.86x | 1.01x |
| Price / BookPrice ÷ Book value/share | — | — | 1.16x | 27.85x | 1.60x |
| Price / FCFMarket cap ÷ FCF | 6.50x | — | 14.71x | 22.74x | 8.99x |
Profitability & Efficiency
MANH leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MANH delivers a 78.2% return on equity — every $100 of shareholder capital generates $78 in annual profit, vs $1 for USPH. EPAM carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to USPH's 0.55x. On the Piotroski fundamental quality scale (0–9), RMNI scores 6/9 vs USPH's 5/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | — | +1.4% | +78.2% | +10.7% |
| ROA (TTM)Return on assets | +8.9% | -19.5% | +0.9% | +28.0% | +8.1% |
| ROICReturn on invested capital | — | -5.3% | +5.6% | +2.4% | +15.5% |
| ROCEReturn on capital employed | +55.0% | -7.2% | +7.6% | +76.3% | +13.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | — | — | 0.55x | 0.36x | 0.04x |
| Net DebtTotal debt minus cash | -$92M | $179M | $390M | -$216M | -$1.2B |
| Cash & Equiv.Liquid assets | $120M | $10M | $36M | $329M | $1.3B |
| Total DebtShort + long-term debt | $28M | $188M | $426M | $112M | $144M |
| Interest CoverageEBIT ÷ Interest expense | 16.13x | -1.57x | 15.42x | — | — |
Total Returns (Dividends Reinvested)
RMNI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MANH five years ago would be worth $10,805 today (with dividends reinvested), compared to $1,872 for SPWR. Over the past 12 months, RMNI leads with a +18.3% total return vs SPWR's -42.4%. The 3-year compound annual growth rate (CAGR) favors RMNI at -0.4% vs SPWR's -42.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +3.7% | -38.2% | -24.6% | -14.2% | -47.9% |
| 1-Year ReturnPast 12 months | +18.3% | -42.4% | -14.3% | -21.9% | -34.4% |
| 3-Year ReturnCumulative with dividends | -1.3% | -81.3% | -43.7% | -15.3% | -55.0% |
| 5-Year ReturnCumulative with dividends | -49.7% | -81.3% | -43.4% | +8.1% | -77.3% |
| 10-Year ReturnCumulative with dividends | -60.1% | -81.3% | +22.6% | +145.1% | +48.8% |
| CAGR (3Y)Annualised 3-year return | -0.4% | -42.8% | -17.4% | -5.4% | -23.4% |
Risk & Volatility
Evenly matched — RMNI and USPH each lead in 1 of 2 comparable metrics.
Risk & Volatility
USPH is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than SPWR's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RMNI currently trades 73.2% from its 52-week high vs SPWR's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 2.13x | 0.93x | 1.10x | 1.21x |
| 52-Week HighHighest price in past year | $5.38 | $2.27 | $93.50 | $247.22 | $222.53 |
| 52-Week LowLowest price in past year | $2.87 | $0.81 | $58.55 | $119.06 | $99.67 |
| % of 52W HighCurrent price vs 52-week peak | +73.2% | +44.9% | +63.1% | +58.1% | +46.9% |
| RSI (14)Momentum oscillator 0–100 | 62.5 | 45.9 | 46.1 | 50.6 | 22.5 |
| Avg Volume (50D)Average daily shares traded | 365K | 1.7M | 171K | 678K | 1.3M |
Analyst Outlook
USPH leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: RMNI as "Hold", SPWR as "Hold", USPH as "Buy", MANH as "Buy", EPAM as "Buy". Consensus price targets imply 1450.0% upside for SPWR (target: $16) vs 37.4% for MANH (target: $197). USPH is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $7.17 | $15.81 | $102.00 | $197.25 | $197.00 |
| # AnalystsCovering analysts | 5 | 45 | 12 | 15 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.1% | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 5 | 2 | — |
| Dividend / ShareAnnual DPS | — | — | $1.80 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.1% | 0.0% | +0.6% | +3.7% | 0.0% |
MANH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RMNI leads in 2 (Valuation Metrics, Total Returns). 1 tied.
RMNI vs SPWR vs USPH vs MANH vs EPAM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RMNI or SPWR or USPH or MANH or EPAM a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus -1. 7% for Rimini Street, Inc. (RMNI). Rimini Street, Inc. (RMNI) offers the better valuation at 10. 1x trailing P/E (9. 5x forward), making it the more compelling value choice. Analysts rate U. S. Physical Therapy, Inc. (USPH) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RMNI or SPWR or USPH or MANH or EPAM?
On trailing P/E, Rimini Street, Inc.
(RMNI) is the cheapest at 10. 1x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, SunPower Inc. is actually cheaper at 5. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Rimini Street, Inc. wins at 0. 49x versus Manhattan Associates, Inc. 's 1. 25x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — RMNI or SPWR or USPH or MANH or EPAM?
Over the past 5 years, Manhattan Associates, Inc.
(MANH) delivered a total return of +8. 1%, compared to -81. 3% for SunPower Inc. (SPWR). Over 10 years, the gap is even starker: MANH returned +145. 1% versus SPWR's -81. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RMNI or SPWR or USPH or MANH or EPAM?
By beta (market sensitivity over 5 years), U.
S. Physical Therapy, Inc. (USPH) is the lower-risk stock at 0. 93β versus SunPower Inc. 's 2. 13β — meaning SPWR is approximately 129% more volatile than USPH relative to the S&P 500. On balance sheet safety, EPAM Systems, Inc. (EPAM) carries a lower debt/equity ratio of 4% versus 55% for U. S. Physical Therapy, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RMNI or SPWR or USPH or MANH or EPAM?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus -1. 7% for Rimini Street, Inc. (RMNI). On earnings-per-share growth, the picture is similar: Rimini Street, Inc. grew EPS 197. 5% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, SPWR leads at 65. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RMNI or SPWR or USPH or MANH or EPAM?
Manhattan Associates, Inc.
(MANH) is the more profitable company, earning 20. 3% net margin versus -10. 5% for SunPower Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MANH leads at 26. 1% versus -2. 0% for SPWR. At the gross margin level — before operating expenses — RMNI leads at 60. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RMNI or SPWR or USPH or MANH or EPAM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Rimini Street, Inc. (RMNI) is the more undervalued stock at a PEG of 0. 49x versus Manhattan Associates, Inc. 's 1. 25x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, SunPower Inc. (SPWR) trades at 5. 1x forward P/E versus 26. 8x for Manhattan Associates, Inc. — 21. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SPWR: 1450. 0% to $15. 81.
08Which pays a better dividend — RMNI or SPWR or USPH or MANH or EPAM?
In this comparison, USPH (3.
1% yield) pays a dividend. RMNI, SPWR, MANH, EPAM do not pay a meaningful dividend and should not be held primarily for income.
09Is RMNI or SPWR or USPH or MANH or EPAM better for a retirement portfolio?
For long-horizon retirement investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). SunPower Inc. (SPWR) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (USPH: +22. 6%, SPWR: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RMNI and SPWR and USPH and MANH and EPAM?
These companies operate in different sectors (RMNI (Technology) and SPWR (Energy) and USPH (Healthcare) and MANH (Technology) and EPAM (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: RMNI is a small-cap deep-value stock; SPWR is a small-cap quality compounder stock; USPH is a small-cap high-growth stock; MANH is a small-cap quality compounder stock; EPAM is a small-cap high-growth stock. USPH pays a dividend while RMNI, SPWR, MANH, EPAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.